Comparison 3. Platinum vs non‐platinum regimens (subgroup analysis 2: by type of platinum agent in platinum arm).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Overall survival	6	958	(Exp[(O‐E) / V], Fixed, 95% CI)	0.85 [0.73, 1.00]
3.1.1 Cisplatin in platinum arm	2	289	(Exp[(O‐E) / V], Fixed, 95% CI)	0.90 [0.69, 1.18]
3.1.2 Carboplatin in platinum arm	4	669	(Exp[(O‐E) / V], Fixed, 95% CI)	0.83 [0.68, 1.00]
3.2 Progression‐free survival/time to progression	8	1077	(Exp[(O‐E) / V], Fixed, 95% CI)	0.77 [0.68, 0.88]
3.2.1 Cisplatin in platinum arm	2	289	(Exp[(O‐E) / V], Fixed, 95% CI)	0.69 [0.54, 0.90]
3.2.2 Carboplatin in platinum arm	6	788	(Exp[(O‐E) / V], Fixed, 95% CI)	0.80 [0.69, 0.93]
3.3 Objective tumour response rate (assessable participants)	10	1205	Risk Ratio (M‐H, Fixed, 95% CI)	1.40 [1.22, 1.59]
3.3.1 Cisplatin in platinum arm	6	552	Risk Ratio (M‐H, Fixed, 95% CI)	1.61 [1.36, 1.89]
3.3.2 Carboplatin in platinum arm	4	653	Risk Ratio (M‐H, Fixed, 95% CI)	1.16 [0.93, 1.44]
3.4 Treatment‐related death (safety population)	5	843	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.24, 4.61]
3.4.1 Cisplatin in platinum arm	2	289	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
3.4.2 Carboplatin in platinum arm	3	554	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.24, 4.61]
3.5 Nausea/vomiting (safety population)	3	655	Risk Ratio (M‐H, Fixed, 95% CI)	4.77 [1.93, 11.81]
3.5.1 Cisplatin in platinum arm	2	289	Risk Ratio (M‐H, Fixed, 95% CI)	10.89 [2.08, 56.90]
3.5.2 Carboplatin in platinum arm	1	366	Risk Ratio (M‐H, Fixed, 95% CI)	2.47 [0.79, 7.74]
3.6 Anaemia (safety population)	5	843	Risk Ratio (M‐H, Fixed, 95% CI)	3.80 [2.25, 6.42]
3.6.1 Cisplatin in platinum arm	2	289	Risk Ratio (M‐H, Fixed, 95% CI)	6.50 [2.86, 14.77]
3.6.2 Carboplatin in platinum arm	3	554	Risk Ratio (M‐H, Fixed, 95% CI)	2.27 [1.11, 4.62]
3.7 Hair loss (safety population)	2	602	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 8.04]
3.7.1 Cisplatin in platinum arm	1	236	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
3.7.2 Carboplatin in platinum arm	1	366	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 8.04]
3.8 Leukopenia (safety population)	5	843	Risk Ratio (M‐H, Fixed, 95% CI)	1.09 [0.84, 1.42]
3.8.1 Cisplatin in platinum arm	2	289	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.79, 1.36]
3.8.2 Carboplatin in platinum arm	3	554	Risk Ratio (M‐H, Fixed, 95% CI)	1.55 [0.58, 4.12]
3.9 Treatment discontinuation due to adverse event (safety population)	5	843	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.59, 1.32]
3.9.1 Cisplatin in platinum arm	2	289	Risk Ratio (M‐H, Fixed, 95% CI)	0.50 [0.05, 5.44]
3.9.2 Carboplatin in platinum arm	3	554	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.60, 1.36]